Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868713 | 0.85 | CFTR (0.32) | CFTRMEN1KMT2A | |
| SCHEMBL17878118 | 0.84 | PARP1 (0.35) | PARP1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL17878119 | 0.84 | PARP1 (0.35) | PARP1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL17878115 | 0.84 | PARP1 (0.35) | PARP1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL17868691 | 0.84 | PARP1 (0.35) | PARP1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL17868643 | 0.81 | RBP4 (0.37) | HTT | |
| SCHEMBL17877360 | 0.78 | PARP1 (0.35) | PARP1CFTRMEN1KMT2A | |
| SCHEMBL17868203 | 0.78 | PARP1 (0.35) | PARP1CFTRMEN1KMT2A | |
| SCHEMBL17868204 | 0.78 | PARP1 (0.35) | PARP1CFTRMEN1KMT2A | |
| SCHEMBL28970110 | 0.77 | PARP1 (0.35) | PARP1CFTRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518057-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077800-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | PARP1 3072/4885CFTR 1945/4885ALDH1A1 1370/4885 |
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | PARP1 3072/4885CFTR 1945/4885ALDH1A1 1370/4885 |
| US-20160185778-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | PARP1 3072/4885CFTR 1945/4885ALDH1A1 1370/4885 |
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | PARP1 3072/4885CFTR 1945/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.